NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

NCT04862455 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

14

Enrollment

OTHER

Sponsor class

Stopped \<75% participation

Conditions

Metastatic Head and Neck Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma

Interventions

OTHER: Hafnium Oxide-containing Nanoparticles NBTXR3
RADIATION: Hypofractionated Radiation Therapy
BIOLOGICAL: Pembrolizumab
RADIATION: Stereotactic Body Radiation Therapy

Sponsor

M.D. Anderson Cancer Center